'Leclaza’s 5 counts of clinical results' to be showcased
By Son, Hyung-Min | translator Kang, Shin-Kook
24.05.02 05:20:28
가나다라
0
Korean pharma and biotech companies to showcase their results at the 2024 American Society of Clinical Oncology (ASCO 2024) Annual Meeting
Yuhan·Janssen to disclose five counts of Leclaza+Rybrevant combination therapy clinical results
HLB to disclose study results of liver cancer tracking…GI Innovation will showcase its ABL
It has been noted whether new anti-cancer candidates from the pharmaceutical and biotech industry in South Korea will be competitive on a global setting.
According to industry sources on April 2nd, various Korean pharmaceutical companies, including Yuhan, HLB, and GI Innovation, will attend the 2024 American Society of Clinical Oncology (ASCO 2024) Annual Meeting, which will take place on 31st for five days in Chicago, United States. The AACR is the world’s largest cancer academic conference, at which 400 companies from 120 countries gather annually to present their latest clinical data.
Yuhan-Janssen will disclose their major clinical data of Leclaza+Rybrevant
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)